Uriah is the CEO of Nucleo Technologies Inc ("NucleoTech") a US Biotech developing Neuro-oncology therapeutics. NucleoTech has a unique approach to BBB-transmigrating protein carriers for Drug delivery to the CNS of Biologics and and RNA therapeutics.As a molecular neurobiologist, Uriah has a broad interest in Brain cell-biology, RNA biology as well as biochemical and molecular tools. He brings with him a track record in Biotech strategy and intellectual property. Uriah's research years (Ph.D. with Prof. Hermona Soreq, MSc with S. Kadener) focused on neurodegenerative conditions using a variety of scientific methods and procedures of molecular biology, biochemistry, and bioinformatics. Uriah is passionate about how well-planned R&D generates strategic IP, which in turn provides the edge needed in the biotech space. Uriah is also a patent agent with the USPTO, loving father of four, occasional runner and meditator, as well as player of Clash Royale.